INCY Incyte Corporation Stock Quote

INCY [NASD]

Index	S&P 500	P/E	-	EPS (ttm)	-1.57	Insider Own	0.40%	Shs Outstand	218.78M	Perf Week	-3.49%
Market Cap	19.01B	Forward P/E	25.48	EPS next Y	3.55	Insider Trans	-5.52%	Shs Float	215.56M	Perf Month	4.97%
Income	-334.50M	PEG	-	EPS next Q	0.75	Inst Own	94.80%	Short Float	2.21%	Perf Quarter	0.03%
Sales	2.46B	P/S	7.74	EPS this Y	304.40%	Inst Trans	0.02%	Short Ratio	4.26	Perf Half Y	-13.02%
Book/sh	10.93	P/B	8.29	EPS next Y	663.50%	ROA	-10.50%	Target Price	105.44	Perf Year	12.33%
Cash/sh	8.27	P/C	10.96	EPS next 5Y	25.85%	ROE	-14.40%	52W Range	62.48 - 110.36	Perf YTD	4.12%
Dividend	-	P/FCF	-	EPS past 5Y	55.60%	ROI	13.70%	52W High	-17.95%	Beta	0.79
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	33.40%	Gross Margin	95.70%	52W Low	44.94%	ATR	2.67
Employees	1456	Current Ratio	3.60	Sales Q/Q	12.50%	Oper. Margin	-13.60%	RSI (14)	56.13	Volatility	2.50% 2.98%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-111.80%	Profit Margin	-13.60%	Rel Volume	0.83	Prev Close	92.04
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 05 BMO	Payout	-	Avg Volume	1.12M	Price	90.56
Recom	2.20	SMA20	2.21%	SMA50	6.05%	SMA200	-2.61%	Volume	928,849	Change	-1.61%

Jan-07-21

Initiated

Truist

Buy

$120

Jan-04-21

Upgrade

Guggenheim

Neutral → Buy

Jun-16-20

Initiated

The Benchmark Company

Hold

May-06-20

Downgrade

JP Morgan

Overweight → Neutral

$89 → $99

Apr-29-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$94

Apr-01-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$83 → $90

Mar-24-20

Resumed

William Blair

Outperform

Mar-13-20

Upgrade

BofA/Merrill

Neutral → Buy

$83

Feb-04-20

Resumed

BofA/Merrill

Neutral

$82

Jan-03-20

Reiterated

BMO Capital Markets

Market Perform

$85 → $74

Jan-03-20

Downgrade

Mizuho

Buy → Neutral

$98 → $79

Jan-02-20

Downgrade

Guggenheim

Buy → Neutral

Oct-03-19

Initiated

Mizuho

Buy

$95

Sep-12-19

Initiated

BMO Capital Markets

Market Perform

Sep-05-19

Upgrade

Oppenheimer

Perform → Outperform

$100

Sep-05-19

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$107

Sep-05-19

Resumed

Morgan Stanley

Equal-Weight

$82 → $87

May-21-19

Initiated

Credit Suisse

Neutral

$75

May-03-19

Downgrade

Barclays

Overweight → Equal Weight

$90 → $82

Apr-11-19

Initiated

Stifel

Hold

$82

Jan-13-21 07:25AM	The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga
Jan-11-21 10:04AM	Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab Zacks
08:46AM	Regeneron (REGN) Upgrade Lifts Range-Bound Biotech Stocks Investopedia
Jan-06-21 11:14AM	Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates Zacks
Dec-31-20 08:52AM	Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment Zacks
Dec-30-20 02:42PM	Incyte Higher on Plan to Develop Treatment for Myelofibrosis TheStreet.com
07:30AM	Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804 Business Wire
Dec-21-20 03:43PM	Is INCY A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-15-20 10:37AM	Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint Zacks
Dec-14-20 03:36PM	Is Incyte Ready for a Sustained Turn to the Upside? TheStreet.com +6.78%
01:15AM	Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm Business Wire
Dec-11-20 02:01PM	Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine PR Newswire
Dec-09-20 08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Dec-07-20 10:00AM	Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Business Wire
10:00AM	Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020 Business Wire
Dec-05-20 11:32AM	Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? Zacks
Dec-04-20 12:30PM	Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Business Wire
Nov-25-20 08:03AM	Frost & Sullivan Reveals Four Key Areas Driving Growth of the Global Gigabit Ethernet Testing Market CNW Group
Nov-24-20 01:21PM	The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer Zacks
Nov-20-20 10:03AM	Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19 Zacks
Nov-19-20 05:20PM	Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 PR Newswire
Nov-12-20 10:26AM	Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal Zacks
08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
07:44AM	The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga
Nov-11-20 04:02PM	Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab Business Wire
03:15AM	These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden MarketWatch
Nov-10-20 07:30AM	These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable Investor's Business Daily
Nov-09-20 08:00AM	Data from Incytes Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting Business Wire
Nov-08-20 08:20AM	Incyte Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Simply Wall St.
Nov-05-20 08:00PM	Incyte Corp (INCY) Q3 2020 Earnings Call Transcript Motley Fool -7.19%
04:11PM	Incyte Earnings Miss Expectations; Tightens Outlook For Top Product Investor's Business Daily
10:12AM	Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong Zacks
08:15AM	Incyte (INCY) Q3 Earnings and Revenues Miss Estimates Zacks
07:00AM	Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
06:15AM	Incyte Corp. to Host Earnings Call ACCESSWIRE
Nov-04-20 03:55PM	More than 40 Abstracts from Incytes Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting Business Wire +7.37%
08:25AM	Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More Zacks
Nov-03-20 07:31AM	Incyte Corp (INCY) Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-02-20 02:00PM	ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis PR Newswire
Oct-31-20 10:45AM	EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis PR Newswire
05:29AM	Point/Counterpoint: The Case for Eli Lilly Investing.com
Oct-30-20 09:00AM	Incyte Ranked Second Among Science Magazines 2020 Top Biopharma Employers Business Wire
06:45AM	Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata PR Newswire
Oct-29-20 12:35PM	Incyte (INCY) Expected to Beat Earnings Estimates: Should You Buy? Zacks
10:51AM	Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results? Zacks
08:00AM	Pooled Results from Incytes TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments Business Wire
Oct-27-20 04:29PM	Novartis Earnings Top, Sales Miss; NVS Stock Falls Investor's Business Daily
04:25PM	Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials Investor's Business Daily
Oct-20-20 08:00AM	Incyte to Report Third Quarter Financial Results Business Wire
Oct-08-20 11:39AM	Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen PR Newswire
Oct-05-20 12:48PM	Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics Business Wire
Sep-18-20 03:48PM	Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments MarketWatch
12:11PM	Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists MarketWatch
07:44AM	CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis PR Newswire
06:00AM	Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal Business Wire
Sep-17-20 04:31PM	Eli Lilly, Amgen Teaming Up On Covid-19 Treatments Investor's Business Daily
04:03PM	Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Business Wire
Sep-16-20 01:57PM	Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients Barrons.com
Sep-15-20 08:43PM	Incyte Corporation (INCY) Fell Out Of Favor With Hedge Funds Insider Monkey
Sep-14-20 04:38PM	Gilead Makes Its Biggest Buy Ever And Gets A 'Flagship' Cancer Drug Investor's Business Daily +5.85%
04:31PM	Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data Investor's Business Daily
03:15PM	Balloons at Macys Thanksgiving Day Parade Will Be Rigged to Special Vehicles Barrons.com
07:48AM	Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time MarketWatch
06:30AM	Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial PR Newswire
Sep-09-20 10:05AM	Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community Business Wire
Sep-04-20 06:28PM	Analyst Report: Incyte Corporation Morningstar Research
Sep-03-20 11:31AM	Incyte (INCY) Down 2.2% Since Last Earnings Report: Can It Rebound? Zacks
Sep-02-20 05:04PM	Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM Business Wire
Sep-01-20 08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Aug-18-20 04:02PM	National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas Business Wire
Aug-07-20 09:11AM	NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment MarketWatch
Aug-04-20 04:11PM	Incyte Earnings Soar 65%, Easily Beating Views Investor's Business Daily
03:00PM	Incyte Corp (INCY) Q2 2020 Earnings Call Transcript Motley Fool
10:10AM	Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi Zacks
09:58AM	Dow Jones Today Dips, Nasdaq Fights To Extend Streak; Take-Two, SolarEdge, AMD Rocket Investor's Business Daily
08:45AM	Incyte (INCY) Q2 Earnings and Revenues Beat Estimates Zacks
07:00AM	Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
Aug-03-20 09:55AM	Dow Jones Today, Stocks Rise As Microsoft Courts TikTok; Varian Soars On Siemens Deal; Incyte, Co-Diagnostics FDA News Investor's Business Daily
08:38AM	Is a Surprise Coming for Incyte (INCY) This Earnings Season? Zacks
08:21AM	Dow Jone Today Boosted By Microsoft TikTok Talks: Varian Soars On Siemens Deal; Incyte,Co-Diagnostics FDA News Investor's Business Daily
02:08AM	Incyte, MorphoSys Win FDA Nod For Key Revenue Driver Tafasitamab SmarterAnalyst
Jul-31-20 07:51PM	FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire
Jul-30-20 07:32PM	10 Biggest Biotechnology Companies Investopedia
Jul-28-20 12:33PM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? Zacks
11:40AM	Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings? Zacks
Jul-27-20 01:54PM	Does Incyte's (NASDAQ:INCY) CEO Salary Compare Well With Industry Peers? Simply Wall St.
Jul-24-20 02:06PM	5 High-Yield Drug Stocks That Are Undervalued With Great Upside InvestorPlace
Jul-23-20 07:15AM	Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints Business Wire
Jul-20-20 12:53PM	Incyte Could Rise Another 15% From Here TheStreet.com +5.36%
Jul-16-20 08:00AM	Incyte to Report Second Quarter Financial Results Business Wire
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com
Jul-09-20 02:00PM	Here's Why Incyte Rose 19.1% in the First Half of 2020 Motley Fool
Jul-08-20 02:17PM	Were Hedge Funds Right About Incyte Corporation (INCY)? Insider Monkey
Jun-29-20 07:05AM	Incyte Announces Approval of Tabrecta (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14 Business Wire
Jun-26-20 10:37AM	Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation Zacks
Jun-23-20 10:24AM	Gilead to Start Studies for an Inhaled Version of Remdesivir Zacks
Jun-22-20 12:05PM	Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF Zacks
12:05PM	Nasdaq Continues to Excel : 5 Best Stocks in ETF Zacks
09:34AM	Gilead's stock falls as it announces clinical trial for inhaled remdesivir MarketWatch
08:36AM	Incyte (INCY) Looks Good: Stock Adds 8.3% in Session Zacks

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pasquale Maria E	EVP & General Counsel	Jan 11	Option Exercise	65.36	127	8,301	30,073	Jan 13 04:15 PM
Pasquale Maria E	EVP & General Counsel	Dec 11	Option Exercise	65.36	128	8,366	29,946	Dec 15 04:51 PM
Pasquale Maria E	EVP & General Counsel	Nov 12	Option Exercise	65.36	127	8,301	28,586	Nov 16 04:56 PM
BIENAIME JEAN JACQUES	Director	Nov 10	Sale	83.00	798	66,234	8,646	Nov 12 04:41 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Nov 06	Option Exercise	65.42	961	62,869	28,971	Nov 10 04:26 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Nov 06	Sale	85.17	961	81,848	28,010	Nov 10 04:26 PM
Flannelly Barry P	EVP & General Manager US	Nov 02	Option Exercise	48.44	20,000	968,800	59,984	Nov 04 04:15 PM
Flannelly Barry P	EVP & General Manager US	Nov 02	Sale	86.60	20,000	1,732,000	39,984	Nov 04 04:15 PM
Pasquale Maria E	EVP & General Counsel	Oct 12	Option Exercise	65.36	128	8,366	28,459	Oct 13 05:10 PM
Pasquale Maria E	EVP & General Counsel	Oct 09	Option Exercise	68.62	1,423	97,646	29,754	Oct 13 05:10 PM
Pasquale Maria E	EVP & General Counsel	Oct 09	Sale	95.00	1,423	135,185	28,331	Oct 13 05:10 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Oct 06	Option Exercise	65.42	961	62,869	28,971	Oct 08 04:21 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Oct 06	Sale	91.97	961	88,383	28,010	Oct 08 04:21 PM
Pasquale Maria E	EVP & General Counsel	Sep 11	Option Exercise	65.36	127	8,301	28,331	Sep 14 04:19 PM
Pasquale Maria E	EVP & General Counsel	Sep 10	Option Exercise	65.36	2,193	143,334	30,397	Sep 14 04:19 PM
Pasquale Maria E	EVP & General Counsel	Sep 10	Sale	90.83	2,193	199,190	28,204	Sep 14 04:19 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Sep 08	Option Exercise	65.42	961	62,869	28,971	Sep 10 04:21 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Sep 08	Sale	88.94	961	85,471	28,010	Sep 10 04:21 PM
DIXON WENDY L	Director	Aug 27	Option Exercise	18.97	20,000	379,400	34,243	Aug 31 04:26 PM
DIXON WENDY L	Director	Aug 27	Sale	94.51	20,000	1,890,200	14,243	Aug 31 04:26 PM
Pasquale Maria E	EVP & General Counsel	Aug 10	Option Exercise	65.36	128	8,366	28,204	Aug 12 04:08 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Aug 06	Option Exercise	65.42	961	62,869	28,971	Aug 10 04:20 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Aug 06	Sale	97.80	961	93,986	28,010	Aug 10 04:20 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 16	Sale	103.83	766	79,534	95,468	Jul 17 04:20 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jul 13	Option Exercise	65.42	2,419	158,251	28,010	Jul 14 04:31 PM
Pasquale Maria E	EVP & General Counsel	Jul 10	Option Exercise	65.36	127	8,301	28,076	Jul 14 04:39 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 08	Sale	108.56	610	66,222	96,857	Jul 08 05:27 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jul 08	Sale	108.56	475	51,566	25,926	Jul 08 05:31 PM
Hoppenot Herve	Chairman / CEO	Jul 07	Option Exercise	73.21	89,771	6,572,135	354,907	Jul 07 07:18 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 07	Option Exercise	88.68	10,876	964,484	108,245	Jul 08 05:27 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jul 07	Sale	107.98	3,120	336,898	26,401	Jul 08 05:31 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 07	Sale	109.56	14,159	1,551,326	97,467	Jul 08 05:27 PM
Hoppenot Herve	Chairman / CEO	Jul 07	Sale	110.00	89,771	9,874,810	266,501	Jul 07 07:18 PM
Wenqing Yao	EVP, Head of Discovery Chem	Jul 06	Option Exercise	64.55	16,553	1,068,496	171,906	Jul 07 07:30 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 06	Option Exercise	75.52	33,602	2,537,457	112,882	Jul 07 07:25 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jul 06	Option Exercise	65.42	961	62,869	26,552	Jul 07 07:13 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jul 06	Sale	106.58	961	102,423	25,591	Jul 07 07:13 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 06	Sale	107.25	36,124	3,874,171	100,750	Jul 07 07:25 PM
Wenqing Yao	EVP, Head of Discovery Chem	Jul 06	Sale	107.32	16,553	1,776,468	156,258	Jul 07 07:30 PM
Hoppenot Herve	Chairman / CEO	Jun 26	Option Exercise	64.55	124,148	8,013,753	360,104	Jun 30 04:06 PM
Hoppenot Herve	Chairman / CEO	Jun 26	Sale	102.91	124,148	12,776,071	240,603	Jun 30 04:06 PM
Flannelly Barry P	EVP & General Manager US	Jun 23	Option Exercise	73.21	599	43,853	36,461	Jun 25 05:09 PM
Trower Paul	Principal Accounting Officer	Jun 23	Option Exercise	64.55	6,943	448,171	28,677	Jun 25 05:15 PM
Trower Paul	Principal Accounting Officer	Jun 23	Sale	110.00	6,943	763,730	21,734	Jun 25 05:15 PM
Flannelly Barry P	EVP & General Manager US	Jun 23	Sale	110.00	400	44,000	36,061	Jun 25 05:09 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Jun 22	Sale	105.31	9,000	947,790	21,762	Jun 23 04:17 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jun 19	Option Exercise	72.86	7,866	573,117	32,767	Jun 23 04:33 PM
Pasquale Maria E	EVP & General Counsel	Jun 19	Option Exercise	72.27	1,423	102,840	25,084	Jun 23 04:42 PM
Flannelly Barry P	EVP & General Manager US	Jun 19	Option Exercise	73.21	7,181	525,721	43,043	Jun 23 04:23 PM
Pasquale Maria E	EVP & General Counsel	Jun 19	Sale	100.00	1,423	142,300	23,661	Jun 23 04:42 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jun 19	Sale	105.00	7,866	825,930	24,901	Jun 23 04:33 PM
Flannelly Barry P	EVP & General Manager US	Jun 19	Sale	105.00	7,181	754,005	35,862	Jun 23 04:23 PM
Pasquale Maria E	EVP & General Counsel	Jun 12	Option Exercise	65.36	127	8,301	23,661	Jun 16 04:24 PM
Pasquale Maria E	EVP & General Counsel	Jun 10	Option Exercise	66.64	3,615	240,915	25,726	Jun 12 04:11 PM
Pasquale Maria E	EVP & General Counsel	Jun 10	Sale	94.51	3,615	341,649	23,534	Jun 12 04:11 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jun 08	Option Exercise	65.42	961	62,869	20,948	Jun 10 04:34 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jun 08	Sale	91.87	961	88,287	19,987	Jun 10 04:34 PM
BAKER BROS. ADVISORS LP	Director	May 28	Buy	102.55	2	205	29,313,198	May 28 08:07 PM
Pasquale Maria E	EVP & General Counsel	May 11	Option Exercise	65.36	128	8,366	23,534	May 13 04:38 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	May 06	Option Exercise	65.42	961	62,869	20,948	May 08 04:53 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	May 06	Sale	96.84	961	93,063	19,987	May 08 04:53 PM
BAKER BROS. ADVISORS LP	Director	Apr 28	Option Exercise	13.34	40,000	533,600	29,311,915	Apr 29 04:45 PM
Pasquale Maria E	EVP & General Counsel	Apr 17	Option Exercise	72.27	9,488	685,698	32,837	Apr 20 05:08 PM
Flannelly Barry P	EVP & General Manager US	Apr 17	Option Exercise	73.21	6,583	481,941	41,925	Apr 21 04:28 PM
Trower Paul	Principal Accounting Officer	Apr 17	Option Exercise	64.55	1,143	73,781	22,467	Apr 21 04:35 PM
Trower Paul	Principal Accounting Officer	Apr 17	Sale	100.00	1,143	114,300	21,324	Apr 21 04:35 PM
Flannelly Barry P	EVP & General Manager US	Apr 17	Sale	100.00	6,583	658,300	35,342	Apr 21 04:28 PM
Pasquale Maria E	EVP & General Counsel	Apr 17	Sale	100.00	9,488	948,800	22,899	Apr 20 05:08 PM
Pasquale Maria E	EVP & General Counsel	Apr 16	Option Exercise	68.62	9,488	651,067	32,837	Apr 20 05:08 PM
Pasquale Maria E	EVP & General Counsel	Apr 16	Sale	95.00	9,488	901,360	22,899	Apr 20 05:08 PM
Pasquale Maria E	EVP & General Counsel	Apr 14	Option Exercise	65.36	17,827	1,165,173	40,726	Apr 15 04:57 PM
Pasquale Maria E	EVP & General Counsel	Apr 14	Sale	90.00	17,827	1,604,430	22,899	Apr 15 04:57 PM
Pasquale Maria E	EVP & General Counsel	Apr 13	Option Exercise	65.36	127	8,301	23,864	Apr 15 04:57 PM
Pasquale Maria E	EVP & General Counsel	Apr 13	Sale	85.68	965	82,681	22,899	Apr 15 04:57 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Apr 06	Option Exercise	65.42	3,844	251,474	23,831	Apr 08 04:35 PM
Pasquale Maria E	EVP & General Counsel	Apr 06	Sale	85.00	1,842	156,570	24,254	Apr 08 04:39 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Apr 06	Sale	85.00	3,844	326,740	19,987	Apr 08 04:35 PM
SWAIN PAULA J	EVP, Human Resources	Mar 31	Option Exercise	64.55	2,329	150,337	50,132	Apr 02 05:32 PM
SWAIN PAULA J	EVP, Human Resources	Mar 31	Sale	71.44	2,329	166,384	48,493	Apr 02 05:32 PM
Pasquale Maria E	EVP & General Counsel	Mar 11	Option Exercise	65.36	128	8,366	26,096	Mar 13 04:18 PM
BROOKE PAUL A	Director	Feb 21	Option Exercise	13.34	20,000	266,800	221,584	Feb 25 04:39 PM
SWAIN PAULA J	EVP, Human Resources	Feb 19	Option Exercise	64.55	2,500	161,375	50,993	Feb 21 04:11 PM
SWAIN PAULA J	EVP, Human Resources	Feb 19	Sale	80.00	2,500	200,000	48,493	Feb 21 04:11 PM
Pasquale Maria E	EVP & General Counsel	Feb 10	Option Exercise	65.36	127	8,301	19,087	Feb 12 05:00 PM
Wenqing Yao	EVP, Head of Discovery Chem	Feb 05	Option Exercise	18.32	17,542	321,369	112,850	Feb 07 04:48 PM
Wenqing Yao	EVP, Head of Discovery Chem	Feb 05	Sale	75.97	17,542	1,332,666	95,308	Feb 07 04:48 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience